Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience

•The safety and efficacy benefits of ide-cel were proportionate in young and older patients despite frailty and geriatric characteristics.•Treatment with commercial ide-cel resulted in robust clinical responses and low-grade toxicities in older patients. [Display omitted] The safety and efficacy of chimeric antigen receptor T-cell therapy is not well described in older patients, a population that has higher frailty and comorbidities. In this multicenter retrospective study, we evaluated clinical outcomes along with frailty and geriatric characteristics such as comorbidities, polypharmacy, falls, neuropathy, organ dysfunction, and performance status in younger (aged